A far-reaching understanding of the molecular action mechanism of AT1-receptor antagonists (AIIAs) was obtained by using CHO cells expressing transfected human AT 1-receptors. In this model, direct [3H]-antagonist binding and inhibition of agonist-induced responses (inositol phosphate accumulation) can be measured under identical experimental conditions. Whereas preincubation with a surmountable AIIA (losartan) causes parallel shifts of the angiotensin II (Ang II) concentration-response curve, insurmountable antagonists also cause partial (i.e., 30% for irbesartan, 50% for valsartan, 70% for EXP3174,) to almost complete (95% for candesartan) reductions of the maximal response. The main conclusions are that all investigated antagonists are competitive with respect to Ang II. They bind to a common or overlapping site on the receptor in a mutually exclusive way. Insurmountable inhibition is related to the slow dissociation rate of the antagonist-receptor complex (t 1/2 of 7 minutes for irbesartan, 17 minutes for valsartan, 30 minutes for EXP3174 and 120 minutes for candesartan). Antagonist-bound AT1-receptors can adopt a fast and a slow reversible state. This is responsible for the partial nature of the insurmountable inhibition. The long-lasting effect of candesartan, the active metabolite of candesartan cilexetil, in vascular smooth muscle contraction studies, as well as in in vivo experiments on rat and in clinical studies, is compatible with its slow dissociation from, and continuous recycling between AT1-receptors. This recycling, or `rebinding' takes place because of the very high affinity of candesartan for the AT1-receptor.
Timmermans PB , Benfield P., Chiu AT, Herblin W., Wong PCAngiotensin II receptors, functional correlates . Am J Hypertens1992 ;5:221S-235S.
2.
Timmermans PB , Wong PC, Chiu AT et al. Angiotensin II Receptors, Angiotensin II Receptor Antagonists. Pharmacological Rev1993;45:205-51.
3.
Bumpus FM, Catt KJ, Chiu AT et al. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension1991;17:720-1.
4.
Mukojama M., Nakajima M., Horiuchi M., Sasamura H., Pratt RE, Dzau VJMolecular cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors.JBiol Chem1993;268:24539-42.
5.
Kambayashi Y. , Bardhan S., Takahashi K. et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem1993;268:24543-46.
Zhang JS, Van Meel JCA, Pfaffendorf M., Van Zwieten P.Different types of angiotensin II receptor antagonism induced by BIBS 222 in the rat portal vein, rabbit aorta; the influence of receptor reserve . J Pharmacol Exp Ther1993;269:509-14.
8.
Robertson MJAngiotensin antagonists. In: Leff P (ed). Receptor-based drug design. New York: Marcel Dekker, 1998: 207-23.
9.
Liu YJ, Shankley NP, Welsh NJ, Black JWEvidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible, synoptic action. Br J Pharmacol1992;106:233-41.
10.
Criscione L. , de Gasparo M., Bühlmayer P., Whitebread S., Ramjoué HP, Wood J.Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1 receptor subtype . Br J Pharmacol1993;110:761-71.
11.
Cazaubon C. , Gougat J., Bousquet F. et al. Pharmacological characterization of SR 47436, a new non-peptide AT1 subtype angiotensin II receptor antagonist . J Pharmacol Exp Ther1993;265:826-34.
12.
Noda M., Shibouta Y., Inada Y. et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new neuropeptide AII antagonist. Biochem Pharmacol1993;46:311-18.
13.
Mochizuki S. , Sato T., Furata K. et al. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J Cardiovasc Pharmacol1995;25:22-9.
14.
Wienen W., Mauz ABM, Van Meel JCA, Entzeroth M.Different types of receptor interaction of peptide, nonpeptide angiotensin II antagonists revealed by receptor binding, functional studies. Mol Pharmacol1992;41:1081-9.
15.
de Chaffoy de Courcelles D., Leysen JE, Roevens P., Van Belle H.The serotonin-S2 receptor: a receptor, transducer coupling model to explain insurmountable antagonist effects. Drug Development Research1986;8:173-8.
16.
Robertson MJ , Dougall IG, Harper D., Mckechnie KCW, Leff P.Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol Sci1994;15:364-69.
17.
Dickinson KE , Cohen RB, Skwish S. et al. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174 . Br J Pharmacol1994;113:179-89.
18.
Wienen W., Hauel N.,Van Meel JCA, Narr B., Ries U., Entzeroth M.Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol1993;110:245-52.
19.
Olins GM, Chen ST, McMahon EG, Palomo MA, Reitz DBElucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629.Mol Pharmacol1994;47:115-20.
20.
Aiyar N., Baker E., Vickery-Clark L. et al. Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist. Eur J Pharmacol1995;283:63-72.
21.
Cirillo R., Renzetti AR, Cucchi P. et al. Pharmacology of LR-B/081, a new highly potent, selective, orally active, nonpeptide angiotensin II AT1 receptor antagonist. Br J Pharmacol1995;114:1117-24.
22.
De Arriba AF , Gomez-Casajus LA, Cavalcanti F., Almansa C., Garcia-Rafanel J., Forn J.In vitro pharmacological characterization of a new selective angiotensinAT1 receptor antagonist, UR7280 . Eur J Pharmacol1996;318:341-7.
23.
Ojima M., Inada Y., Shibouta Y. et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol1997;319:137-46.
24.
Robertson MJ , Barnes JC, Drew GM et al. Pharmacological profile of GR 117289 in vitro: a novel, potent, specific nonpeptide angiotensin AT1 receptor antagonistBr JPharmacol1992 ;107:1173-80.
25.
Panek RL, Lu GH, Overhisser RW, Major TC, Hodges JC, Taylor DGFunctional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J Pharm Exp Ther1995;273:753-61.
26.
Koh E., Morimoto S.,Tomita J. et al. Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, hypertrophy of cultured vascular smooth muscle cells. J Cardiovasc Pharmacol1994;23:175-9.
27.
Perlman S., Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA, Schwartz TWNon-peptide angiotensin agonist. Functional, molecular interaction with the AT1 receptor. J Biol Chem1995;270:1493-6.
28.
Balmforth AJ , Lee AL,Warburton P., Donnelly D., Ball SGThe conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III ,VII. J Biol Chem1997; 272:4245-51.
29.
Vanderheyden PML , Fierens FLP, De Backer JP, Frayman N., Vauquelin G.Distinction between surmountable, insurmountable selective AT1-receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1-receptors. Brit J Pharmacol1999;126:1057-65.
30.
Fierens FLP , Vanderheyden PML, De Backer JP, Vauquelin G.Insurmountable angiotensin II AT1 receptor antagonists: the role of tight antagonist binding . Eur J Pharmacol1999;372:199-206.
31.
Vanderheyden PML , Fierens FLP, De Backer JP, Vauquelin G.Reversible and syntopic interaction between angiotensin II AT1 receptor antagonists, human AT1 receptors expressed in CHO-K1 cells. Biochem Pharmacol2000;59:927-35.
32.
Verheijen I. , Fierens FLP , De Backer JP, Vauquelin G., Vanderheyden PMLInteraction between the partially insurmountable antagonist valsartan, human recombinant angiotensin II type 1 receptors. Fund Clin Pharmacol2001;14:577-85.
33.
Pendleton RG , Gessner G., Horner E.Studies on inhibition of angiotensin II receptors in rabbit adrenal, aorta . J Pharmacol Exp Ther1989;248:637-43.
34.
Hara M., Kiyama R., Nakajima S. et al. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor. Eur J Pharmacol1995;289:267-73.
35.
Rang HPThe kinetic action of acetylcholine antagonists in smooth muscle. Proc R Soc Lond1965;164:488-510.
36.
Rang HP, Dale MMMechanisms of drug action. In: Rang HP , Dale MM (eds). Pharmacology. London: Churchill Livingstone, 1987; 3-34.
37.
Kenakin TPDrug antagonism. In: Kenakin TP (ed). Pharmacological Analysis of Drug-Receptor Interaction. New York: Raven Press, 1987:205-44.
38.
Tamura K., Okuhira M., Mikoshiba I., Hashimoto K.In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist. Biol Pharmacol Bull1997;20:850-5.
39.
Wong PC, Timmermans PBNonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP753 . J Pharmacol Exp Ther1991;258:49-57.
40.
Vauquelin G. , Morsing P., Fierens FLP, De Backer JP, Vanderheyden PML.A two-state receptor model for the interaction between angiotensin II AT1 receptors, their non-peptide antagonists. Biochem Pharmacol2001 (in press).
41.
Fierens FLP , Vanderheyden PML, De Backer JP, Vauquelin G.Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor- transfected Chinese hamster ovary cells. Eur J Pharmacol1999;367:413-22.
42.
Vanderheyden PML , Fierens FLP, Verheijen I., De Backer JP, Vauquelin G.Binding characteristics of [3H]-irbesartan to human recombinant angiotensin II type 1 receptors. JRAAS2000;1:159-65.
43.
De Lean A., Stadel J M., Lefkowitz RJA ternary complex model explains the agonist-specific properties of the adenylate cyclase- coupled β-adrenergic receptor. J Biol Chem1980;255:7108-17.
44.
Severne Y., IJzerman A., Nerme V., Zimmerman H., Vauquelin G.Shallow agonist competition binding curves for b-adrenergic receptors: the role for tight agonist binding. Mol Pharmacol1986;31:69-73.
45.
RenzettiA,Cucci P., Guelfi M., Cirillo R., Salimbeni A. ,Giachetti A.Pharmacology of LR-B/057, a novel orally active AT1 receptor antagonist . J Cardiovasc Pharmacol1995; 25:354-60.
46.
Monnot C., Bihoreau C., Conchon S., Curnow KM, Corvol P., Clauser E.Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding, coupling. Reconstitution of the binding site by co-expression of two deficient mutants. J Biol Chem1996;271:1507-13.
47.
Cvejic S., Devi LADimerization of the δ-opioid receptor. J Biol Chem1997;272:26959-64.
48.
Gürdal H., Bond RA, Johnson MD, Friedman E., Onaran HOAn efficacy-dependent effect of cardiac overexpression of β2-adrenoceptor on ligand affinity in transgenic mice. Mol Pharmacol1997;52:187-94.
49.
Anderson KM , Murahashi T., Dorstal DE, Peach MJMorphological, biochemical analysis of angiotensin II internalisation in cultured rat aortic smooth muscle cells. Am J Physiol1993;264:C179-C188.
50.
Hein L., Meinel L., Pratt RE, Dzau VJ, Kobilka BK: Intracellular trafficking of angiotensin II AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol1997;11:1266-77.
51.
Fierens FLP , Vanderheyden PML et al. Tight binding of the insurmountable antagonist [3H]candesartan to angiotensin II AT1 receptors in intact cells is apparently unrelated to receptor internalisation. Biochem Pharmacol (submitted)
52.
Yu SS, Lefkowitz RJ, Hausdorff WPβ-Adrenergic receptor sequestration: a potential mechanism of receptor resensitization. J Biol Chem1993 ;268:337-41
53.
Duncia JV, Chiu AT, Carini DJ et al. The discovery of potent nonpeptide angiotensin II receptors antagonists: a new class of potent antihypertensives.JMed Chem1990;33:1312-29.
54.
Inoue Y., Nakamura N., Inagami T.A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hypertens1997;15:703-14.
55.
Mirua SI, Feng YH, Huasain A., Karnik SSRole of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptorJ Biol Chem1999;274:7103-10.
56.
Fierens FLP , Vanderheyden PML, Gaborik Z. et al. Lys199 Mutation of the human angiotensin II AT1 receptor differently affects the binding of surmountable, insurmountable nonpeptide antagonists. JRAAS2001 (in press).
57.
Limbird LECell Surface Receptors: A Short Course on Theory and Methods, 2nd ed. Boston: KluwerAcad Publ, 1996: 61-122.
58.
Morsing P., Adler G., Brandt-Eliasson U. et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension1999;33:1406-13.
59.
Lacourcière Y., Asmar R.A comparison of the efficacy, duration of action of candesartan cilexetil, losartan as assessed by clinic, ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertens1999;12:1181-7.
60.
Delacrétaz E., Nussberger J., Biollaz J., Waeber B., Brunner HRCharacterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension1995;25:14-21.
